Thynk Capital — Full Portfolio
17 tracked investments · listed companies and verified rows first
Encinitas, US
Edward White(Executive Officer)Charles H. Silver(Executive Officer, Director)Edgar F. Berner(Director)Craig S. Andrews(Director)David L.R. Stein(Executive Officer)Steven D. Sprenger(Director)
PartnerJim Plante· solo GP
Curtana Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule inhibitors for brain cancer, particularly pediatric high-grade glioma.
BiotechMedical DevicesAustin, US
PartnerJim Plante· solo GP
E-Band designs and manufactures millimeter-wave wireless systems for 5G networks and ultra-low-latency applications such as high-frequency trading, multimedia, and gaming.
Hardware
PartnerJim Plante· solo GP
Elevian is a biotechnology company developing rGDF11, a recombinant protein therapy shown in preclinical animal models to promote recovery of motor function after ischemic and hemorrhagic stroke by stimulating new blood vessel formation, neurogenesis, and reducing inflammation.
BiotechHealthtechLongevityMenlo Park, US
Mark Allen(Executive Officer, Director)Casey J McGlynn(Executive Officer)Sebastian Giwa(Executive Officer, Director)Luis Alvarez(Executive Officer)Daniel Marshak(Director)
BoardSuzanne Fletcher(Director)
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersBOLD CapitalFor Good VenturesLauder PartnersPrime Movers LabWTI
Manhattan Beach, US
Geeta Gupta(Executive Officer, Director, Promoter)Henrik Fisker(Executive Officer, Director, Promoter)William R. McDermott(Director)Mark Hickson(Director)Roderick K. Randall(Director)
BoardNadine Watt(Director)
PartnerJim Plante· solo GP
Co-investorsCapital Q® Ventures Inc.
Geospan provides software tools (gSquare and gPro) that generate 99% accurate 3D roof measurements and estimates using aerial photography and patented technology for construction, insurance, real estate, and public security professionals.
Construction TechPropTechSaaS
PartnerJim Plante· solo GP
PartnerJim Plante· solo GP
IVIVA Medical develops fully implantable bioartificial kidneys as a potential cure for patients with chronic kidney disease, diabetes, and kidney failure.
BiotechHealthtechMedical Devices
PartnerJim Plante· solo GP
Co-investorsBold Capital PartnersPrime Movers Lab
Mercer Island, US
Ronald Berenson(Executive Officer, Director, Promoter)
PartnerJim Plante· solo GP
Co-investorsElevate CapitalPallasite Ventures
Klotho Therapeutics uses biotechnology to develop therapeutics that mimic the natural human Klotho protein to address age-related diseases including cognitive decline, kidney failure, diabetes, and cancer.
BiotechLongevity
PartnerJim Plante· solo GP
Lübris BioPharma develops recombinant human lubricin for treating dry eye, osteoarthritis, and age/inflammation-related conditions.
BiotechHealthtechMedical Devices
PartnerJim Plante· solo GP
Co-investorsTarnagulla Ventures
BiotechSyracuse, US
Guilherme Cherman Perdigao de Oliveira(Executive Officer, Director)Reason("CEO's full legal name is ""Reason""")Anthony Matthew Chow(Director)
BoardKelsey Moody(Director)
PartnerJim Plante· solo GP
Co-investorsquadraScope Venture Fund
SmartDrive Systems provides video-based fleet safety and analytics solutions for commercial transportation companies, including trucking fleets and transit systems, to prevent collisions and improve driver performance.
Enterprise SoftwareIoTLogistics & Supply ChainSaaS
PartnerJim Plante· solo GP
Co-investorsNewView CapitalOak Investment PartnersSixth Street
Theragene Pharmaceuticals develops immunotherapy and gene therapy treatments for cancer and cardiovascular diseases using AAV technology.
BiotechDigital HealthMedical DevicesSan Diego, US
Jon Berglin(Executive Officer, Director)
BoardSteven Davis(Director)Daniel Coury(Director)Chaojie Zhang(Director)
PartnerJim Plante· solo GP
Viscient develops 3D human tissue models for drug development, replacing animal models in preclinical and clinical testing.
BiotechDeep TechDigital Health
PartnerJim Plante· solo GP
BiotechSan Diego, US
Stan Kim(Executive Officer, Director)Nigel Calcutt(Director)
PartnerJim Plante· solo GP
X4 Pharmaceuticals develops and commercializes therapies for rare immune system diseases, including XOLREMDI (mavorixafor), which received U.S. approval, and is running a Phase 3 trial in chronic neutropenic disorders.
BiotechHealthtechMedical DevicesBoston, US
PartnerJim Plante· solo GP
Co-investorsLumira VenturesPartners Resolute
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.